A multicenter retrospective study was designed to assess clinical outcome of COVID-19 in patients with hematological malignancies (HM) following treatment with anti-SARS-CoV-2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non-randomized administration of CP in this high-risk cohort of patients from the Italian Hematology Alliance on COVID-19 (ITA-HEMA-COV) project, now including 2049 untreated control patients. We investigated 30- and 90-day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS-CoV-2 clearance in 79 CP recipients and compared results with 158 propensity score-matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID-19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM.

Lanza, F., Monaco, F., Ciceri, F., Cairoli, R., Sacchi, M.v., Guidetti, A., et al. (2022). Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study. HEMATOLOGICAL ONCOLOGY [10.1002/hon.3060].

Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study

Venditti, Adriano;
2022-08-06

Abstract

A multicenter retrospective study was designed to assess clinical outcome of COVID-19 in patients with hematological malignancies (HM) following treatment with anti-SARS-CoV-2 convalescent plasma (CP) or standard of care therapy. To this aim, a propensity score matching was used to assess the role of non-randomized administration of CP in this high-risk cohort of patients from the Italian Hematology Alliance on COVID-19 (ITA-HEMA-COV) project, now including 2049 untreated control patients. We investigated 30- and 90-day mortality, rate of admission to intensive care unit, proportion of patients requiring mechanical ventilatory support, hospitalization time, and SARS-CoV-2 clearance in 79 CP recipients and compared results with 158 propensity score-matched controls. Results indicated a lack of efficacy of CP in the study group compared with the untreated group, thus confirming the negative results obtained from randomized studies in immunocompetent individuals with COVID-19. In conclusion, this retrospective analysis did not meet the primary and secondary end points in any category of immunocompromized patients affected by HM.
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15
English
COVID-19
convalescent plasma
disease severity
hematological malignancy
survival data
Lanza, F., Monaco, F., Ciceri, F., Cairoli, R., Sacchi, M.v., Guidetti, A., et al. (2022). Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study. HEMATOLOGICAL ONCOLOGY [10.1002/hon.3060].
Lanza, F; Monaco, F; Ciceri, F; Cairoli, R; Sacchi, Mv; Guidetti, A; Marchetti, M; Massaia, M; Arcaini, L; Krampera, M; Mohamed, S; Gherlinzoni, F; Mecucci, C; Gentile, M; Romano, I; Venditti, A; Ruggeri, M; Ferrero, D; Coviello, E; Fabbri, E; Corradini, P; Passamonti, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Hematological Oncology - 2022 - Lanza - Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant.pdf

accesso aperto

Descrizione: Lavoro
Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 230.36 kB
Formato Adobe PDF
230.36 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/305198
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact